



AusBiotech2009
AUSTRALIA'S BIOTECHNOLOGY CONFERENCE

Asia Pacific
Region of Opportunities

27 to 30 October 2009 Melbourne Convention and Exhibition Centre

Host Industry Body



Host State Partner



Supported By



www.ausbiotech2009.com.au



Sarah Holland
Global Head, CNS Partnering
Pharma Partnering
Roche Pharmaceuticals



Sarah Holland is the CNS therapy area lead for Roche Pharma Partnering, based in Basel, Switzerland. Since joining Roche in 2005, Sarah has been responsible for evaluating licensing opportunities in a range of disease areas, including the Plexikon deal on b-raf inhibitors, the Memory deal

on Nicotinic alpha-7 agonists and the Evotec deal on NR2B NMDA antagonists. Sarah's group recently initiated a collaboration in the area of neuronal stem cells and a discovery alliance with PTC Therapeutics.

Prior to joining Roche, Sarah was Global Brand Director at AstraZeneca for a hormonal agent for breast cancer during US and EU launch. She held various commercial and strategic roles over her ten years there, including Global Strategic Planning Manager for early compounds, Pricing Strategist and Health Economist.

Sarah's interest in the CNS field dates back to the start of her industry career at Amersham International (now GE Healthcare), where she was International Product Manager for an innovative agent for imaging brain blood flow.

Sarah gained her MBA from Manchester Business School, where she was a Visiting Fellow until 2004, and her DPhil and first degree at Oxford University.